Kheirolomoom, Azadeh; Kare, Aris J.; Ingham, Elizabeth S.; Paulmurugan, Ramasamy; Robinson, Elise R.; Baikoghli, Mo; Inayathullah, Mohammed; Seo, Jai W.; Wang, James; Fite, Brett Z.; Wu, Bo; Tumbale, Spencer K.; Raie, Marina N.; Cheng, R. Holland; Nichols
Ex vivo programming of T cells can be efficacious but is complex and expensive; therefore, the development of methods to transfect T cells in situ is important. We developed and optimized anti-CD3-targeted lipid nano-particles (aCD3-LNPs) to deliver tightly packed, reporter gene mRNA specifically to T cells. In vitro, targeted LNPs efficiently delivered mCherry mRNA to Jurkat T cells, and T-cell activation and depletion were associated with aCD3 antibody coating on the surface of LNPs. aCD3-LNPs, but not non-targeted LNPs, accumulated within the spleen following systemic injection, with mCherry and Fluc signals visible within 30 min after injection. At 24 h after aCD3-LNP injection, 2-4% of all splenic T cells and 2-7% of all circulating T cells expressed mCherry, and this was dependent on aCD3 coating density. Targeting and transfection were accompanied by systemic CD25(+), OX40(+), and CD69(+) T-cell activation with temporary CD3e ligand loss and depletion of splenic and circulating subsets. Migration of splenic CD8a(+) T cells from the white-pulp to red-pulp, and differentiation from naive to memory and effector phenotypes, followed upon aCD3-LNP delivery. Additionally, aCD3-LNP injection stimulated the secretion of myeloid-derived chemokines and T-helper cytokines into plasma. Lastly, we administered aCD3-LNPs to tumor bearing mice and found that transfected T cells localized within tumors and tumor-draining lymph nodes following immunotherapy treatment. In summary, we show that CD3-targeted transfection is feasible, yet associated with complex immunological consequences that must be further studied for potential therapeutic applications.
Keywords: T-cell transfection; T-cell activation; mRNA; Reporter gene; Lipid nanoparticle
In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles represents a cutting-edge approach in immunotherapy, aiming to enhance the body's natural ability to fight diseases like cancer and viral infections. T-cells are a crucial component of the immune system, responsible for identifying and attacking infected or malignant cells. However, in many cases, T-cells need to be genetically modified to improve their efficacy against specific targets, a process known as transfection. Traditional methods of T-cell transfection often involve ex vivo manipulation, where T-cells are extracted from the body, genetically modified in the lab, and then reintroduced into the patient. This process is complex, costly, and time-consuming. In situ transfection offers a promising alternative by delivering genetic material directly into T-cells within the body. Anti-CD3-conjugated lipid nanoparticles are at the heart of this innovation. These nanoparticles are designed to specifically target T-cells by binding to the CD3 receptor, a molecule present on the surface of T-cells. The lipid nanoparticles encapsulate the desired genetic material, protecting it from degradation and facilitating its entry into the T-cells upon binding to CD3. This targeted delivery system ensures that the genetic material reaches the T-cells efficiently, leading to effective transfection.
Product Name | Catalog | Unit Size | Price |
---|---|---|---|
ExplantMag Transfection Reagent | WHM-OB10 | 250 µL, 500 µL | INQUIRY |
Hela Transfection Reagent | WHM-OB12 | 40 µL, 500 µL, 1 mL, 5x 1 mL | INQUIRY |
BiochemFect Transfection Reagent | WHM-OB14 | 50 µL, 500 µL, 1 mL, 5x 1 mL | INQUIRY |
BiochemFect Gold Transfection Reagent | WHM-OB15 | 40 µL, 500 µL, 1 mL, 5x 1 mL | INQUIRY |
BiochemFect Stem Transfection Reagent | WHM-OB16 | 50 µL, 500 µL, 1 mL | INQUIRY |
EcoFect Transfection Reagent | WHM-OB17 | 50 µL, 500 µL, 1 mL, 3x 1 mL | INQUIRY |
Vero Transfection Reagent | WHM-OB18 | 50 µL, 250 µL, 500 µL, 1 mL, 5x 1 mL | INQUIRY |
Insect Transfection Reagent | WHM-OB19 | 50 µL, 500 µL, 1 mL, 5x 1 mL | INQUIRY |
lMagFec Transfection Reagent | WHM-OB21-1 | 200 µL, 500 µL, 1 mL, 3x 1 mL | INQUIRY |
siRNA Transfection Selection Kit | WHM-OB2A | 1 Kit | INQUIRY |
Silent siRNA Transfection Reagent | WHM-OB22 | 50 µL, 500 µL, 1 mL, 3x 1 mL | INQUIRY |
Silent Stem siRNA Transfection Reagent | WHM-OB23 | 50 µL, 500 µL, 1 mL | INQUIRY |
Golden Tran-D | CDSNT42 | 0.1 mL, 1.5 mL, 1.0 mL, 0.5 mL, 2.0 mL, 5.0 mL, 3.0 mL | INQUIRY |
Golden Tran-DR | CDSNT43 | 0.1 mL, 1.5 mL, 1.0 mL, 0.5 mL, 2.0 mL, 5.0 mL, 3.0 mL | INQUIRY |
Golden Tran-vivo | CDSNT44 | 0.1 mL, 1.5 mL, 1.0 mL, 0.5 mL, 2.0 mL, 5.0 mL, 3.0 mL | INQUIRY |
Golden Tran-R | CDSNT45 | 0.1 mL, 1.5 mL, 1.0 mL, 0.5 mL, 2.0 mL, 5.0 mL, 3.0 mL | INQUIRY |